Effect of camrelizumab combined with SOX chemotherapy regimen in the treatment of patients with advanced gastric cancer and its influences on tumor marker levels and survival
Objective To analyze the effect of camrelizumab combined with SOX chemotherapy regimen in the treatment of patients with advanced gastric cancer and its influences on tumor marker levels and survival.Methods A total of 100 patients with advanced gastric cancer admitted from February 2020 to April 2023 were selected as the study subjects and randomly divided into control group and observation group,with 50 cases in each group.The control group was treated with SOX chemotherapy regimen,and the observation group was treated with camrelizumab on the basis of the control group.The therapeutic effects of the two groups were compared.Results The total effective rate of treatment in the observation group was higher than that in the control group(P<0.05).After treatment,the levels of carcinoembryonic antigen(CEA),vascular endothelial growth factor(VEGF),cytokeratin 19 fragment antigen 21-1(CYFRA21-1)and carbohydrate antigen 19-9(CA19-9)in the observation group were lower than those in the control group(P<0.05).After treatment,the scores of each dimension of the World Health Organization Quality of Life-BREF(WHOQOL-BREF)in the observation group were higher than those in the control group(P<0.05).The total incidence of adverse reactions in the observation group was lower than that in the control group(P<0.05).Conclusion Camrelizumab combined with SOX chemotherapy regimen is effective in the treatment of advanced gastric cancer.It can reduce the levels of tumor markers,improve survival of patients,and will not increase the risk of adverse reactions,which is worthy of futher clinical promotion and application.
万方数据
维普
